360 related articles for article (PubMed ID: 17853306)
1. Topical pimecrolimus: a new horizon for vitiligo treatment?
Sendur N; Karaman G; Saniç N; Savk E
J Dermatolog Treat; 2006; 17(6):338-42. PubMed ID: 17853306
[TBL] [Abstract][Full Text] [Related]
2. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo.
Stinco G; Piccirillo F; Forcione M; Valent F; Patrone P
Eur J Dermatol; 2009; 19(6):588-93. PubMed ID: 19651562
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study.
Dawid M; Veensalu M; Grassberger M; Wolff K
J Dtsch Dermatol Ges; 2006 Nov; 4(11):942-6. PubMed ID: 17081269
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study.
Farajzadeh S; Daraei Z; Esfandiarpour I; Hosseini SH
Pediatr Dermatol; 2009; 26(3):286-91. PubMed ID: 19706089
[TBL] [Abstract][Full Text] [Related]
5. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo.
Köse O; Arca E; Kurumlu Z
J Dermatolog Treat; 2010 May; 21(3):133-9. PubMed ID: 20394489
[TBL] [Abstract][Full Text] [Related]
6. Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series.
Lonsdale-Eccles AA; Velangi S
Br J Dermatol; 2005 Aug; 153(2):390-4. PubMed ID: 16086755
[TBL] [Abstract][Full Text] [Related]
7. Pimecrolimus cream in repigmentation of vitiligo.
Seirafi H; Farnaghi F; Firooz A; Vasheghani-Farahani A; Alirezaie NS; Dowlati Y
Dermatology; 2007; 214(3):253-9. PubMed ID: 17377388
[TBL] [Abstract][Full Text] [Related]
8. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects.
Lotti T; Buggiani G; Troiano M; Assad GB; Delescluse J; De Giorgi V; Hercogova J
Dermatol Ther; 2008 Jul; 21 Suppl 1():S20-6. PubMed ID: 18727812
[TBL] [Abstract][Full Text] [Related]
9. Topical tacrolimus for treatment of childhood vitiligo in Asians.
Kanwar AJ; Dogra S; Parsad D
Clin Exp Dermatol; 2004 Nov; 29(6):589-92. PubMed ID: 15550128
[TBL] [Abstract][Full Text] [Related]
10. Topical pimecrolimus in the treatment of vitiligo.
Boone B; Ongenae K; Van Geel N; Vernijns S; De Keyser S; Naeyaert JM
Eur J Dermatol; 2007; 17(1):55-61. PubMed ID: 17324829
[TBL] [Abstract][Full Text] [Related]
11. Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion.
Hartmann A; Bröcker EB; Hamm H
J Dtsch Dermatol Ges; 2008 May; 6(5):383-5. PubMed ID: 18042249
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial.
Esfandiarpour I; Ekhlasi A; Farajzadeh S; Shamsadini S
J Dermatolog Treat; 2009; 20(1):14-8. PubMed ID: 18608735
[TBL] [Abstract][Full Text] [Related]
13. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo.
Coskun B; Saral Y; Turgut D
Eur J Dermatol; 2005; 15(2):88-91. PubMed ID: 15757818
[TBL] [Abstract][Full Text] [Related]
14. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo.
Kumaran MS; Kaur I; Kumar B
J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):269-73. PubMed ID: 16503885
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of pimecrolimus cream 1% for treatment of facial vitiligo.
Mayoral FA; Vega JM; Stavisky H; McCormick CL; Parneix-Spake A
J Drugs Dermatol; 2007 May; 6(5):517-21. PubMed ID: 17679186
[TBL] [Abstract][Full Text] [Related]
16. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea.
Karabulut AA; Izol Serel B; Eksioglu HM
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):729-34. PubMed ID: 18328059
[TBL] [Abstract][Full Text] [Related]
17. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
[TBL] [Abstract][Full Text] [Related]
18. Topical immunomodulators are effective for treatment of vitiligo.
Choi CW; Chang SE; Bak H; Choi JH; Park HS; Huh CH; Kim CW; Kim SE; Mun SK; Kim BJ; Kim MN
J Dermatol; 2008 Aug; 35(8):503-7. PubMed ID: 18789070
[TBL] [Abstract][Full Text] [Related]
19. Time-kinetic study of repigmentation in vitiligo patients by tacrolimus or pimecrolimus.
Lubaki LJ; Ghanem G; Vereecken P; Fouty E; Benammar L; Vadoud-Seyedi J; Dell'Anna ML; Briganti S; Picardo M; Heenen M
Arch Dermatol Res; 2010 Mar; 302(2):131-7. PubMed ID: 19547993
[TBL] [Abstract][Full Text] [Related]
20. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease.
Zuberbier T; Bräutigam M
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):718-21. PubMed ID: 18312323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
